Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With Other Antiretroviral Agents in People Living With HIV

Inclusion Criteria

• •Antiretroviral (ARV) naive with no use of any ARV within one month of screening. Use of pre-exposure prophylaxis (PrEP) (any duration), post-exposure prophylaxis (PEP) (any duration), or HIV-1 treatment (\< 10 days therapy total) \> 1 month prior to screening is permitted
• •HIV-1 ribonucleic acid (RNA) ≥ 200 copies/mL at screening
• •Cluster Determinant 4+ (CD4+) cell count ≥ 200 cells/microliter at screening